WallStreetZenWallStreetZen

NASDAQ: DNTH
Dianthus Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for DNTH

Based on 7 analysts offering 12 month price targets for Dianthus Therapeutics Inc

Min Forecast
$113.00+37.17%
Avg Forecast
$135.14+64.05%
Max Forecast
$158.00+91.79%

Should I buy or sell DNTH stock?

Based on 7 analysts offering ratings for Dianthus Therapeutics Inc.

Strong Buy
Strong Buy
4 analysts 57.14%
Buy
3 analysts 42.86%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although DNTH's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates DNTH as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +5.11% per year. Learn More

Be the first to know when Wall Street analysts revise their DNTH stock forecasts and price targets.

DNTH stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-10-27
lockedlocked$00.00+00.00%2026-10-15
lockedlocked$00.00+00.00%2026-09-11
lockedlocked$00.00+00.00%2026-09-04
lockedlocked$00.00+00.00%2026-08-06Find Out Why
Wedbush
Top 5%
96
BuyMaintains$122.00+48.09%2026-08-05
Evercore ISI Group
Bottom 12%
12
BuyMaintains$134.00+62.66%2026-08-03

1 of 1

Forecast return on equity

Is DNTH forecast to generate an efficient return?

Company
-17.23%
Industry
21.35%
Market
172.15%
DNTH's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is DNTH forecast to generate an efficient return on assets?

Company
-16.64%
Industry
21.87%
DNTH is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

DNTH earnings per share forecast

What is DNTH's earnings per share in the next 3 years based on estimates from 18 analysts?

Avg 1 year Forecast
-$3.89
Avg 2 year Forecast
-$4.77
Avg 3 year Forecast
-$5.55

DNTH revenue forecast

What is DNTH's revenue in the next 3 years based on estimates from 17 analysts?

Avg 1 year Forecast
$2.1M+8.04%
Avg 2 year Forecast
$2.0M+6.36%
Avg 3 year Forecast
$15.2M+697.74%
DNTH's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

DNTH revenue growth forecast

How is DNTH forecast to perform vs Biotechnology companies and vs the US market?

Company
86.12%
Industry
30.08%
Market
12.75%
DNTH's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
DNTH's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

DNTH vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
DNTH$82.38$135.14+64.05%Strong Buy
TVTX$50.39$75.63+50.08%Strong Buy
DFTX$36.33$70.25+93.37%Strong Buy
ADPT$26.64$29.50+10.74%Strong Buy
CRSP$51.42$73.00+41.97%Buy
View Top Biotech Stocks

Dianthus Therapeutics Stock Forecast FAQ

Is Dianthus Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 7 Wall Street analysts covering (NASDAQ: DNTH) stock is to Strong Buy DNTH stock.

Out of 7 analysts, 4 (57.14%) are recommending DNTH as a Strong Buy, 3 (42.86%) are recommending DNTH as a Buy, 0 (0%) are recommending DNTH as a Hold, 0 (0%) are recommending DNTH as a Sell, and 0 (0%) are recommending DNTH as a Strong Sell.

If you're new to stock investing, here's how to buy Dianthus Therapeutics stock.

What is DNTH's earnings growth forecast for 2026-2028?

(NASDAQ: DNTH) Dianthus Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.65%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.44%.

Dianthus Therapeutics's earnings in 2026 is -$192,246,000.On average, 18 Wall Street analysts forecast DNTH's earnings for 2026 to be -$217,495,235, with the lowest DNTH earnings forecast at -$224,744,331, and the highest DNTH earnings forecast at -$198,511,108. On average, 18 Wall Street analysts forecast DNTH's earnings for 2027 to be -$266,566,465, with the lowest DNTH earnings forecast at -$316,286,534, and the highest DNTH earnings forecast at -$207,320,772.

In 2028, DNTH is forecast to generate -$310,228,841 in earnings, with the lowest earnings forecast at -$416,599,247 and the highest earnings forecast at -$175,605,980.

What is DNTH's revenue growth forecast for 2026-2028?

(NASDAQ: DNTH) Dianthus Therapeutics's forecast annual revenue growth rate of 88.37% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 29.74%, and it is also forecast to beat the US market's average forecast revenue growth rate of 12.61%.

Dianthus Therapeutics's revenue in 2026 is $1,904,000.On average, 17 Wall Street analysts forecast DNTH's revenue for 2026 to be $115,057,016, with the lowest DNTH revenue forecast at $65,778,829, and the highest DNTH revenue forecast at $189,114,132. On average, 17 Wall Street analysts forecast DNTH's revenue for 2027 to be $113,267,115, with the lowest DNTH revenue forecast at $0, and the highest DNTH revenue forecast at $352,386,581.

In 2028, DNTH is forecast to generate $849,587,267 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $6,429,656,751.

What is DNTH's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: DNTH) forecast ROA is -16.64%, which is lower than the forecast US Biotechnology industry average of 21.83%.

What is DNTH's Price Target?

According to 7 Wall Street analysts that have issued a 1 year DNTH price target, the average DNTH price target is $135.14, with the highest DNTH stock price forecast at $158.00 and the lowest DNTH stock price forecast at $113.00.

On average, Wall Street analysts predict that Dianthus Therapeutics's share price could reach $135.14 by Oct 27, 2027. The average Dianthus Therapeutics stock price prediction forecasts a potential upside of 64.05% from the current DNTH share price of $82.38.

What is DNTH's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: DNTH) Dianthus Therapeutics's current Earnings Per Share (EPS) is -$4.24. On average, analysts forecast that DNTH's EPS will be -$3.89 for 2026, with the lowest EPS forecast at -$4.02, and the highest EPS forecast at -$3.55. On average, analysts forecast that DNTH's EPS will be -$4.77 for 2027, with the lowest EPS forecast at -$5.65, and the highest EPS forecast at -$3.71. In 2028, DNTH's EPS is forecast to hit -$5.55 (min: -$7.45, max: -$3.14).

What is DNTH's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: DNTH) forecast ROE is -17.23%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.